• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Bios September 8, 2021

Jon C. Mirsalis

Vice President, SRI Biosciences

Jon C. Mirsalis, Ph.D., DABT, has more than 35 years of experience in the management and conduct of preclinical development projects for the translation of pharmaceutical products, vaccines, and medical devices into human clinical trials. A large portion of his career has focused on accelerating development of therapies for infectious diseases and biothreat agents, including fast-tracking therapies for influenza, Ebola, plague, anthrax TB and drug-resistant bacteria.

Mirsalis joined SRI in 1981 as a staff scientist, and subsequently served as a program director, department director, laboratory director, associate director, and managing director. He currently serves as VP of SRI’s Translational Development Section, a 90-person group that is the largest contractor of preclinical services to the National Institutes of Health.

Mirsalis has a broad background in drug development and has personally been involved in the development of more than 70 therapeutics that have entered clinical trials. Approximately 15 have achieved market approval.  He has also published extensively in the areas of genetic toxicology, mechanisms of carcinogenesis, development of therapeutics for cancer and infectious disease, and use of transgenic animals; he is the author of more than 200 publications, book chapters, and abstracts.

Before joining SRI, Mirsalis was a postdoctoral fellow at the Chemical Industry Institute of Toxicology, where he developed the in vivo-in vitro hepatocyte DNA repair assay, which is now used as a screen to identify potential carcinogens by government and industry. Mirsalis regularly lectures on drug development at the University of California-San Francisco, on global health at Notre Dame University and on biosecurity at Stanford University.  He recently completed two terms as Chair of the Board of Directors of the California Biomedical Research Association and in 2020 he joined the Board of the National Association of Biomedical Research.  He currently serves on the Advisory Council for the Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) and the Medical CBRN Defense Consortium (MCDC).  He has previously served on the Board of Scientific Councilors for the National Toxicology Program and the FDA’s Over-the-Counter Product Review Committee.

Mirsalis received his B.S. degree in zoology/molecular biology from Kent State University, his M.S. degree in genetics from North Carolina State University, and holds Ph.D. degrees in toxicology and genetics from North Carolina State University. He has been certified by the American Board of Toxicology since 1983.

He was named an SRI Fellow in 2014.

Recent publications

more +
  • Enhancement of sensitivity and quantification quality in the LC-MS/MS measurement of large biomolecules with sum of MRM (SMRM)

    We describe here an approach to boost detection sensitivity and expand dynamic range in the quantitation of large molecules while maintaining analytical specificity using summation of MRM (SMRM) transitions and LC separation technique.

  • Serum Biomarkers Reveal Long-term Cardiac Injury in Isoproterenol-treated African Green Monkeys

    In this study, we have used filter-aided sample preparation (FASP) and tandem mass tag (TMT) labeling to investigate serum protein alterations in isoproterenol-treated African green monkeys.

  • In Vivo Activity of Amodiaquine against Ebola Virus Infection

    We investigated the potential anti-EBOV effect of amodiaquine in a well-characterized nonhuman primate model of EVD.

  • Increased stress associated with head-out plethysmography testing can exacerbate respiratory effects and lead to mortality in rats

    The generalized stress inherent to head-out plethysmography testing exacerbated the respiratory effects of DSM421 and was possibly compounded by DSM421’s cardiovascular effects, thus artifactually resulting in moribundity and mortality in rats.

  • Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy

    Clinically relevant linezolid regimens were simulated in the in vitro hollow-fiber infection model (HFIM) system to identify the linezolid therapies that minimize toxicity, maximize antibacterial activity, and prevent drug resistance.

  • Preclinical Studies on the Pharmacokinetics, Safety, and Toxicology of Oxfendazole: Toward First in Human Studies

    A 2-week study in rats identified target organs of oxfendazole toxicity to be bone marrow, epididymis, liver, spleen, testis, and thymus.

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2023 SRI International
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}